Quadrant Capital Group’s BridgeBio Pharma BBIO Stock Holding History

Quadrant Capital Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-175	Closed	-$2K	–	2535
2022 Q1	$2K	Sell	175 -27	-13%	-$277	﹤0.01%	2127
2021 Q4	$3K	Sell	202 -16	-7%	-$677	﹤0.01%	2004
2021 Q3	$10K	Buy	218 +5	+2%	+$268	﹤0.01%	1569
2021 Q2	$13K	Buy	213 +2	+0.9%	+$114	﹤0.01%	1421
2021 Q1	$13K	Buy	211 +14	+7%	+$916	﹤0.01%	1373
2020 Q4	$14K	Hold	197	–	–	﹤0.01%	1223
2020 Q3	$7K	Hold	197	–	–	﹤0.01%	1358
2020 Q2	$6K	Buy	+197	New	+$6K	﹤0.01%	1551

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's BBIO Position: Q2 2022 in Review

Quadrant Capital Group sold out of BridgeBio Pharma (BBIO) in Q2 2022, closing a stake of 175 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in BBIO in Q2 2020 and held it in 8 quarters. The position peaked at $14K in Q4 2020. 164 funds tracked by Wall St. Rank hold BBIO as of Q2 2022.

Quadrant Capital Group reported no remaining BridgeBio Pharma position as of Q2 2022 after selling out during the quarter.
Quadrant Capital Group sold 175 BridgeBio Pharma shares in Q2 2022, an estimated $2K.
Quadrant Capital Group first reported a position in BridgeBio Pharma in Q2 2020 and held it in 8 quarters.
Quadrant Capital Group's BridgeBio Pharma position peaked at $14K in Q4 2020.
164 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.